Porton Biopharma Limited has been working to support Ohara Pharmaceutical Co. Ltd. who have today announced that they have obtained marketing approval for Erwinase® from the Ministry of Health Labour and Welfare in Japan.
PBL will be active at a number of international conferences this autumn. For more details or to arrange a meeting with us please see the details here, or contact us via email.
PBL have appointed Amir Malik as finance director to assist with strategic planning and direction. Amir has almost 20 years experience in a range of strategic finance roles, is a qualified chartered accountant, has an MBA in finance and a BSc in Chemistry, and brings a wealth of experience of working in both the public and private sectors
Our latest cohort of staff have been independently assessed and achieved a whole series of level 2 and 3 NVQ awards, the awards are in subjects including storage & warehousing and laboratory skills.
In a “ground breaking ceremony” led by Baroness Scott of Bybrook OBE, Porton Biopharma Ltd (PBL) has begun the construction of a new pharmaceutical development facility which will provide state-of–the–art facilities for its teams of scientists.
We are pleased to announce that we have appointed Nigel Brooksby as a new Non Executive Director to the PBL Board. Nigel will take up his position from June and brings to the Board his considerable knowledge and experience in biopharmaceuticals and life-sciences.
In a “ground breaking ceremony” led by MP for Salisbury John Glen, Porton Biopharma Ltd (PBL) has initiated the construction of a new multi-million pound facility. The investment will see the creation of a pharmaceutical process facility that contains a new large state-of-the-art fermenter, process train and associated utilities.
PBL has enjoyed considerable success during its first year of operation by meeting all of our milestones and by investing in both staff and facilities.